First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
"Management emphasized, 'Our technology is proving to be a game-changer in mental health treatment.'"
Moat: BrainsWay's proprietary technology and strong clinical data create a significant barrier to entry for competitors.
growth - Investors are likely attracted to the high revenue growth rate (37.8% YoY) and potential for market expansion.
Minimal impact from interest rates as the company has low debt levels (Debt/Equity of 0.09) and does not rely heavily on financing…
Watch on earnings: Number of new device installations per quarter, Clinical trial outcomes and their impact on market expansion, Revenue from service contracts and maintenance.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $68M to $85M as recent clinical trials show a 60% improvement in patient outcomes for depression.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.